Edgewise reports Q4 2022 net loss $19.4M; cash $352M; advancing EDG-5506 and EDG-7500 trials

Edgewise Therapeutics, Inc.

2022-FY EPS reported -$1.26

Cash, cash equivalents and marketable securities of $352M as of Dec 31, 2022.
Q4 2022 net loss $19.4M ($0.31 per share); R&D expenses $16.6M, G&A $5.5M.
EDG-7500 for HCM entered IND-enabling studies; Phase 1 start expected 2H2023.
LYNX Phase 2 DMD trial interim data expected Q4 2023; ARCH BMD 12-month data Q2 2023.
CANYON BMD trial to be amended with potentially registration-enabling cohort in 2H2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.